Free Trial

GRI Bio (GRI) Competitors

GRI Bio logo
$1.66 +0.16 (+10.67%)
As of 09/5/2025 04:00 PM Eastern

GRI vs. NXTC, SNGX, TXMD, LGVN, HCWB, BFRG, IMCC, MRKR, LPTX, and MBRX

Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include NextCure (NXTC), Soligenix (SNGX), TherapeuticsMD (TXMD), Longeveron (LGVN), HCW Biologics (HCWB), Bullfrog AI (BFRG), IM Cannabis (IMCC), Marker Therapeutics (MRKR), Leap Therapeutics (LPTX), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry.

GRI Bio vs. Its Competitors

GRI Bio (NASDAQ:GRI) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

GRI Bio has a beta of -1.59, meaning that its stock price is 259% less volatile than the S&P 500. Comparatively, NextCure has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

GRI Bio presently has a consensus price target of $22.00, indicating a potential upside of 1,225.30%. NextCure has a consensus price target of $25.50, indicating a potential upside of 418.82%. Given GRI Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe GRI Bio is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
NextCure
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

NextCure's return on equity of -106.62% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -327.62% -191.40%
NextCure N/A -106.62%-85.20%

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 0.9% of GRI Bio shares are owned by insiders. Comparatively, 17.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NextCure is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$8.21M-$11.56-0.14
NextCureN/AN/A-$55.65M-$25.82-0.19

In the previous week, GRI Bio had 1 more articles in the media than NextCure. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for NextCure. GRI Bio's average media sentiment score of 0.99 beat NextCure's score of 0.50 indicating that GRI Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRI Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

GRI Bio beats NextCure on 7 of the 12 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRI vs. The Competition

MetricGRI BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.77M$3.12B$5.77B$9.91B
Dividend YieldN/A2.29%6.71%4.52%
P/E Ratio-0.1420.9775.5426.08
Price / SalesN/A290.04480.4288.33
Price / CashN/A44.9736.9659.01
Price / Book0.229.8611.446.09
Net Income-$8.21M-$53.47M$3.28B$266.14M
7 Day Performance19.42%2.92%0.96%0.34%
1 Month Performance32.80%9.83%7.83%4.42%
1 Year Performance-80.95%15.97%62.64%26.17%

GRI Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRI
GRI Bio
3.2084 of 5 stars
$1.66
+10.7%
$22.00
+1,225.3%
-80.1%$3.77MN/A-0.141News Coverage
Short Interest ↓
High Trading Volume
NXTC
NextCure
4.6018 of 5 stars
$5.03
-1.9%
$25.50
+407.0%
-71.6%$13.46MN/A-0.1990News Coverage
Short Interest ↓
SNGX
Soligenix
2.5083 of 5 stars
$3.10
+1.3%
$6.00
+93.5%
-31.1%$13.28M$120K-0.8220Short Interest ↓
TXMD
TherapeuticsMD
0.2231 of 5 stars
$1.11
-0.9%
N/A-39.3%$12.85M$1.76M0.00420
LGVN
Longeveron
2.5033 of 5 stars
$0.83
-0.2%
$7.67
+825.8%
-63.3%$12.57M$2.39M-0.1320Short Interest ↑
HCWB
HCW Biologics
2.9561 of 5 stars
$5.72
+0.7%
$35.00
+511.9%
-81.1%$12.31M$2.57M-0.4140Short Interest ↓
BFRG
Bullfrog AI
0.7207 of 5 stars
$1.21
-1.6%
N/A-54.2%$12.20M$60K-1.594
IMCC
IM Cannabis
0.1893 of 5 stars
$2.32
-4.9%
N/A-11.7%$12.17M$39.44M-4.30340News Coverage
Short Interest ↑
Gap Down
MRKR
Marker Therapeutics
3.9844 of 5 stars
$0.93
+3.3%
$13.17
+1,322.3%
-71.3%$11.98M$6.59M-0.6860Positive News
Short Interest ↓
LPTX
Leap Therapeutics
1.5051 of 5 stars
$0.29
-2.3%
$3.38
+1,070.2%
-90.3%$11.95MN/A-0.1840
MBRX
Moleculin Biotech
3.1676 of 5 stars
$0.39
-0.2%
$4.00
+919.4%
-84.9%$11.88MN/A0.0020Analyst Revision
Gap Down

Related Companies and Tools


This page (NASDAQ:GRI) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners